FGFR-specific tyrosine kinase inhibitors (F-TKIs) provide clinical benefit in iCCA, but FGFR2 fusion proteins carrying mutations in key tumor-associated sites confer a growth advantage to tumor cells and increase resistance to selective TKIs. Here, FGFR2 is linked to neoplasm.